Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor replacement therapy has been the standard of care in hemophilia, although there are limitations to this approach. More recently, the approval of novel gene therapies has presented a promising option for patients with both hemophilia A and B.
In this podcast, you will hear from Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, and Johannes Oldenburg, MD, University Clinic Bonn, Bonn, Germany, who discuss the current standard of care in hemophilia and share some insights into the value of gene therapies.
The post Hemophilia: the current standard of care and the value of novel gene therapies appeared first on VJHemOnc.
